GSK and CureVac sign £132m deal to develop next-generation COVID-19 vaccine
pharmafile | February 3, 2021 | News story | Research and Development | COVID-19, CureVac, GlaxoSmithKline
GlaxoSmithKline (GSK) and CureVac have today announced they are joining forces to develop a new COVID-19 vaccine to combat future variants of the virus.
Under the €150 million (£132 million) agreement, the two companies will develop several mRNA vaccine candidates in the hope of bringing broader protection against multiple current and future COVID-19 strains with one vaccine.
The vaccine is scheduled to roll out next year, and will be used to both immunise people for the first time and boost immunity in those who have already received a vaccine.
The partnership between GSK and CureVac also extends to CureVac’s first-generation vaccine candidate, which is currently in Phase IIb/III clinical trials.
GSK plan to manufacture up to 100 million doses of the vaccine this year, in exchange for market authorisation and exclusive rights to develop and commercialise their vaccine in all countries but Austria, Switzerland, and Germany.
Emma Walmsley, CEO of GSK, said: “We believe that next generation vaccines will be crucial in the continued fight against COVID-19.
“This new collaboration builds on our existing relationship with CureVac and means that together, we will combine our scientific expertise in mRNA and vaccine development to advance and accelerate the development of new COVID-19 vaccine candidates.”
Franz-Werner Haas, CEO of CureVac, commented: “With the help of GSK’s proven vaccine expertise, we are equipping ourselves to tackle future health challenges with novel vaccines.”
Jack Goddard
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
